Skip to main content

Table 2 Baseline demographic and clinical features of RA patients in the study

From: CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-κB activation

Characteristic

RA patients (n = 50)

Demographic

 Age, years, median (IQR)

60 (49~ 64)

 Female, n (%)

38 (76)

Disease status

 Disease duration, months, median (IQR)

38 (14–110)

 ESR (mm/h), median (IQR)

80 (54~ 105)

 CRP (mg/dl), median (IQR)

4.37 (1.82~ 6.75)

 Rheumatoid factor-positive, n (%)

46 (92)

 ACPA-positive, n (%)

41 (82)

 DAS28, median (IQR)

5.02 (3.0~ 6.8)

Previous medications, n (%)

 Corticosteroids

19 (38)

 Methotrexate

20 (40)

 Leflunomide

6 (12)

 Sulfasalazine

2 (4)

 Hydroxychloroquine

7 (14)

 Etanercept

5 (10)

  1. RA rheumatoid arthritis, IQR interquartile range, ESR, erythrocyte sedimentation rate, CRP, C-reactive protein, ACPA, anti-cyclic citrullinated peptide antibody, DAS28, Disease Activity Score 28-joint assessment, n, number of patients, SD, standard deviation